Is there evidence to treat heart failure based on race or ethnicity?;Existe evidência para tratar insuficiência cardíaca baseada na raça ou etnia?

Revista da Associacao Medica Brasileira

Volumn 55, Issue 2, 2009, Pages 110-116

  Latado, Adriana Lopes ^a   Lopes, Marcelo Barreto ^b   Passos, Luiz Carlos Santana ^a   Lopes, Antonio Alberto ^a  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^b Hospital Geral Roberto Santos   (Brazil)

Author keywords

Heart failure; Race; Systematic Review; Therapy

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAZOLE DERIVATIVE; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; PROPANOLAMINE DERIVATIVE;

CAUCASIAN; ETHNOLOGY; EVIDENCE BASED MEDICINE; HEART FAILURE; HUMAN; NEGRO; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ADRENERGIC BETA-ANTAGONISTS; AFRICAN CONTINENTAL ANCESTRY GROUP; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARBAZOLES; ENALAPRIL; EUROPEAN CONTINENTAL ANCESTRY GROUP; EVIDENCE-BASED MEDICINE; HEART FAILURE; HUMANS; PROPANOLAMINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 67650311369     PISSN: 01044230     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. Carnethon MR, Lynch EB, Dyer AR, Lloyd-Jones DM, Wang R, Garside DB, et al. Comparison of risk factors for cardiovascular mortality in black and white adults. Arch Intern Med. 2006;166:1196-202.
2. Ferguson JA, Tierney WM, Westmoreland GR, Mamlin LA, Segar DS, Eckert GJ, et al. Examination of racial differences in management of cardiovascular disease. J Am Coll Cardiol. 1997;30:1707-13.
3. Centers for Disease Control and Prevention. Mortality from congestive heart failure-United States, 1980-1990. MMWR Morb Mortal Wkly Rep.1994;43:77-81.
4. Dries DL, Exner DV, Gersh BJ, Cooper HA, Carson PE, Domanski MJ. Racial differences in the outcome of left ventricular dysfunction. N Engl J Med. 1999;340:609-16.
5. Giles WH, Kittner SJ, Hebel JR, Losonczy KG, Sherwin RW. Determinants of black-white differences in the risk of cerebral infarction. The National Health and Nutrition Examination Survey Epidemiologic Follow-up Study. Arch Intern Med.1995;155:1319-24.
6. Rathore SS, Foody JM, Wang Y, Smith GL, Herrin J, Masoudi FA, et al. Race, quality of care, and outcomes of elderly patients hospitalized with heart failure. JAMA. 2003;289:2517-24.
7. Exner DV, Dries DL, Domanski MJ, Cohn JN. Lesser response to angiotensin- converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med.2001;344:1351-7.
8. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med. 1993;328:914-21.
9. Instituto Brasileiro de Geografia e Estatística. Censo Demográfico - 2000 Características Gerais da População - Resultados da Amostra. Disponível em: http://www.ibge.gov.br/home/estatistica/populacao/censo2000/populacao/censo2000_populacao.pdf. Acesso em 28/12/2006.
10. Secretaria de Estado da Saúde de São Paulo. Causas de óbito segundo raça/ cor e gênero no Estado de São Paulo. Rev Saude Publica.2005;39:987-8.
11. Ministério Da Saúde - Secretaria de Gestão Estratégica e Participativa. Política nacional de saúde integral da população negra. Disponível em: http://www.irohin.org.br/docs/politica_nacional_saude_pop_negra.doc. Acesso em: 28/12/2006.
12. Wright JT, Jr., Dunn JK, Cutler JA, Davis BR, Cushman WC, Ford CE, et al. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA. 2005;293:1595-608.
13. Yancy CW, Fowler MB, Colucci WS, Gilbert EM, Bristow MR, Cohn JN, et al. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med 2001;344:1358-65.
14. Dries DL, Strong MH, Cooper RS, Drazner MH. Efficacy of angiotensin- converting enzyme inhibition in reducing progression from asymptomatic left ventricular dysfunction to symptomatic heart failure in black and white patients. J Am Coll Cardiol. 2002;40:311-7.
15. Carson P, Ziesche S, Johnson G, Cohn JN. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. J Card Fail 1999;5:178-87.
16. Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino R Jr, Ferdinand K, etal. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351:2049-57.
17. Luttik ML, Jaarsma T, Moser D, Sanderman R, van Veldhuisen DJ. The importance and impact of social support on outcomes in patients with heart failure: an overview of the literature. J Cardiovasc Nurs 2005; 20: 162-9.
18. Wood AJ. Racial differences in the response to drugs-pointers to genetic differences. N Engl J Med. 2001;344:1394-6.
19. Xie HG, Kim RB, Wood AJ, Stein CM. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol. 2001;41:815-50.
20. Andersson B, Blange I, Sylven C. Angiotensin-II type 1 receptor gene polymorphism and long-term survival in patients with idiopathic congestive heart failure. Eur J Heart Fail.1999;1:363-9.